May 2018 - Cancer Currents Blog
-
New Treatment Approach Could Help Prevent Recurrences of Some Bladder CancersFlushing the bladder with the chemotherapy drug gemcitabine after tumors have been removed surgically may reduce the risk of low-grade bladder cancer returning, according to the results of a large clinical trial.
-
Experimental Cancer Drug Metarrestin Targets Metastatic TumorsResearchers have struggled to develop therapies to treat tumors that have spread to other parts of the body. In a new study, researchers tested whether the experimental drug metarrestin can selectively shrink metastases in mouse models of aggressive pancreatic cancer.
-
Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid CancerFDA recently approved the targeted-drug combination to treat patients with advanced melanoma and a subset of patients with a rare and aggressive form of thyroid cancer whose tumors have a specific mutation in the BRAF gene.
-
Can Immunotherapy Succeed in Glioblastoma?Despite continued efforts to develop new therapies for glioblastoma, none have been able to improve how long patients live appreciably. Despite some setbacks, researchers are hopeful that immunotherapy might be able to succeed where other therapies have not.
-
Some Children with Wilms Tumor Can Receive Less Therapy, Study SuggestsResults from an NCI-sponsored clinical trial may point to an important change in how some children with advanced Wilms tumor, a form of kidney cancer, are treated.
-
FDA Approves Second CAR T-Cell Therapy for LymphomaFDA has approved tisagenlecleucel (Kymriah) for certain kinds of non-Hodgkin lymphoma. Read about the trial that led to the approval and what the approval means for people with lymphoma.
-
FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney CancerFDA has approved the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), as an initial treatment for some patients with advanced kidney cancer. Learn how this approval will affect patient care.
-
Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian CancersFDA has expanded its approval of rucaparib (Rubraca) as a maintenance therapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer whose tumors shrank after subsequent treatment with a platinum-based chemotherapy.
-
Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian CancersScientists have struggled to come up with a simple test to detect endometrial and ovarian cancers early, when they are most likely to respond to treatment. Can a liquid biopsy test called PapSEEK change that?